Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Actinogen Medical (ATGGF) Stock Price & Analysis

24 Followers

ATGGF Stock Chart & Stats

$0.03$0.00(0.00%)
At close: 4:00 PM EST
$0$0.5$1Aug 19Aug 27Sep 24Oct 16Oct 27
Day’s Range
$0.03 - $0.04
52-Week Range
$0.02 - $1.00
Previous Close
$0.03
Volume
N/A
Average Volume (3M)
5,554
Market Cap
$109.38M
Enterprise Value
$90.43M
Total Cash (Recent Filing)
$16.73M
Total Debt (Recent Filing)
$4.78M
Price to Earnings (P/E)
―
Beta
907.16
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Lead Drug Platform

Xanamem provides a defined therapeutic platform with an oral small-molecule approach and a specific biological mechanism. If clinical development succeeds, this could support repeatable commercialization across neurological and neuropsychiatric indications rather than relying on a single narrow use.

Multi-indication Opportunity

The program is being developed across both Alzheimer’s disease and major depressive disorder, creating potential diversification within the pipeline. Progress in either indication could expand the addressable opportunity and improve the strategic value of the underlying technology.

Positive Equity And Moderate Leverage

Positive equity and moderate reported leverage provide a financial cushion relative to a heavily debt-funded development company. This balance-sheet position may preserve some flexibility to continue clinical work, although it does not eliminate the need to manage ongoing cash consumption.

Bears Say

Revenue Has Fallen To Zero

The sharp decline to zero revenue shows that the company currently lacks a dependable commercial top line. Without recurring revenue generation, funding for clinical development depends more heavily on capital availability, making financial progress closely tied to pipeline execution.

Deep And Widening Losses

Large operating and net losses indicate that the business has not yet converted development activity into sustainable profitability. Continued losses can constrain reinvestment capacity and increase the amount of external funding required before the lead program can generate meaningful commercial returns.

Persistent Cash Burn

Persistent negative operating and free cash flow show that the company is not self-funding and that cash use worsened materially in FY2026. Reliance on external capital raises financing risk and may create dilution or other constraints if development spending remains elevated.

Actinogen Medical News

ATGGF FAQ

What was Actinogen Medical ’s price range in the past 12 months?
Actinogen Medical lowest stock price was $0.02 and its highest was $1.00 in the past 12 months.
What is Actinogen Medical ’s market cap?
Actinogen Medical ’s market cap is $109.38M.
When is Actinogen Medical ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actinogen Medical ’s earnings last quarter?
Actinogen Medical released its earnings results on Aug 27, 2026. The company reported -$0.001 earnings per share for the quarter.
Is Actinogen Medical overvalued?
According to Wall Street analysts Actinogen Medical ’s price is currently Undervalued.
Does Actinogen Medical pay dividends?
Actinogen Medical does not currently pay dividends.
What is Actinogen Medical ’s EPS estimate?
Actinogen Medical ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinogen Medical have?
Actinogen Medical has 3,874,168,200 shares outstanding.
What happened to Actinogen Medical ’s price movement after its last earnings report?
Actinogen Medical reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Actinogen Medical ?
Currently, no hedge funds are holding shares in ATGGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology